Logo image of NBRV

NABRIVA THERAPEUTICS PLC (NBRV) Stock Fundamental Analysis

USA - NASDAQ:NBRV - IE000OZRGNV6 - Common Stock

1.42 USD
0 (0%)
Last: 7/31/2023, 8:00:01 PM
1.3986 USD
-0.02 (-1.51%)
After Hours: 7/31/2023, 8:00:01 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NBRV. NBRV was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of NBRV have multiple concerns. NBRV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NBRV has reported negative net income.
NBRV had a negative operating cash flow in the past year.
In the past 5 years NBRV always reported negative net income.
In the past 5 years NBRV always reported negative operating cash flow.
NBRV Yearly Net Income VS EBIT VS OCF VS FCFNBRV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

NBRV has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NBRV Yearly ROA, ROE, ROICNBRV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K

1.3 Margins

With a Gross Margin value of 18.76%, NBRV perfoms like the industry average, outperforming 50.24% of the companies in the same industry.
In the last couple of years the Gross Margin of NBRV has declined.
NBRV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.76%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-38.92%
GM growth 5YN/A
NBRV Yearly Profit, Operating, Gross MarginsNBRV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K

More info and screens

0

2. Health

2.1 Basic Checks

NBRV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NBRV has been increased compared to 1 year ago.
NBRV has a worse debt/assets ratio than last year.
NBRV Yearly Shares OutstandingNBRV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
NBRV Yearly Total Debt VS Total AssetsNBRV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -5.39, we must say that NBRV is in the distress zone and has some risk of bankruptcy.
NBRV has a Altman-Z score of -5.39. This is in the lower half of the industry: NBRV underperforms 66.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.39
ROIC/WACCN/A
WACC6.62%
NBRV Yearly LT Debt VS Equity VS FCFNBRV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

NBRV has a Current Ratio of 0.85. This is a bad value and indicates that NBRV is not financially healthy enough and could expect problems in meeting its short term obligations.
NBRV has a worse Current ratio (0.85) than 90.52% of its industry peers.
A Quick Ratio of 0.52 indicates that NBRV may have some problems paying its short term obligations.
NBRV has a Quick ratio of 0.52. This is amonst the worse of the industry: NBRV underperforms 93.84% of its industry peers.
Industry RankSector Rank
Current Ratio 0.85
Quick Ratio 0.52
NBRV Yearly Current Assets VS Current LiabilitesNBRV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 20.40% over the past year.
NBRV shows a small growth in Revenue. In the last year, the Revenue has grown by 6.16%.
NBRV shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 47.33% yearly.
EPS 1Y (TTM)20.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.93%
Revenue 1Y (TTM)6.16%
Revenue growth 3Y57.35%
Revenue growth 5Y47.33%
Sales Q2Q%-5.36%

3.2 Future

NBRV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.90% yearly.
Based on estimates for the next years, NBRV will show a very strong growth in Revenue. The Revenue will grow by 38.14% on average per year.
EPS Next Y49.57%
EPS Next 2Y39.49%
EPS Next 3Y30.2%
EPS Next 5Y21.9%
Revenue Next Year89.23%
Revenue Next 2Y66.62%
Revenue Next 3Y52.98%
Revenue Next 5Y38.14%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
NBRV Yearly Revenue VS EstimatesNBRV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
NBRV Yearly EPS VS EstimatesNBRV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NBRV. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NBRV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NBRV Price Earnings VS Forward Price EarningsNBRV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NBRV Per share dataNBRV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10

4.3 Compensation for Growth

NBRV's earnings are expected to grow with 30.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.49%
EPS Next 3Y30.2%

More info and screens

0

5. Dividend

5.1 Amount

NBRV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NABRIVA THERAPEUTICS PLC

NASDAQ:NBRV (7/31/2023, 8:00:01 PM)

After market: 1.3986 -0.02 (-1.51%)

1.42

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-10 2023-08-10/amc
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners88.12%
Ins Owner Change0%
Market Cap4.55M
Revenue(TTM)36.51M
Net Income(TTM)-54.07M
Analysts40
Price Target1.02 (-28.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-24.21%
Min Revenue beat(2)-42.32%
Max Revenue beat(2)-6.1%
Revenue beat(4)1
Avg Revenue beat(4)-14.68%
Min Revenue beat(4)-42.32%
Max Revenue beat(4)5.63%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-18.63
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-8.32
FCFYN/A
OCF(TTM)-8.26
OCFYN/A
SpS11.4
BVpS-1.36
TBVpS-1.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.76%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-38.92%
GM growth 5YN/A
F-Score3
Asset Turnover1.5
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 111.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.85
Quick Ratio 0.52
Altman-Z -5.39
F-Score3
WACC6.62%
ROIC/WACCN/A
Cap/Depr(3y)43.48%
Cap/Depr(5y)38.11%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.93%
EPS Next Y49.57%
EPS Next 2Y39.49%
EPS Next 3Y30.2%
EPS Next 5Y21.9%
Revenue 1Y (TTM)6.16%
Revenue growth 3Y57.35%
Revenue growth 5Y47.33%
Sales Q2Q%-5.36%
Revenue Next Year89.23%
Revenue Next 2Y66.62%
Revenue Next 3Y52.98%
Revenue Next 5Y38.14%
EBIT growth 1Y-3.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y59.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.2%
OCF growth 3YN/A
OCF growth 5YN/A

NABRIVA THERAPEUTICS PLC / NBRV FAQ

What is the fundamental rating for NBRV stock?

ChartMill assigns a fundamental rating of 1 / 10 to NBRV.


What is the valuation status for NBRV stock?

ChartMill assigns a valuation rating of 1 / 10 to NABRIVA THERAPEUTICS PLC (NBRV). This can be considered as Overvalued.


How profitable is NABRIVA THERAPEUTICS PLC (NBRV) stock?

NABRIVA THERAPEUTICS PLC (NBRV) has a profitability rating of 0 / 10.